Scarica l'app Stockscreener
43.67
1.28%
0.55
Korro Bio Inc Borsa (KRRO) Ultime notizie
Wellington Management Group LLP Makes New $436,000 Investment in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com India
Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
100-employee biotech opens new Kendall Square HQ - The Business Journals
Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World
Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro secures approvals in Australia to commence AATD trial of KRRO-110 - Yahoo Finance
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
Korro Bio CFO Vineet Agarwal sells $56,000 in stock By Investing.com - Investing.com South Africa
FMR LLC Reduces Stake in Korro Bio Inc - GuruFocus.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock - Investing.com
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Partners with Novo Nordisk, Reports $169M Cash Position Despite Widening Losses | KRRO Stock News - StockTitan
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
Korro Bio (NASDAQ:KRRO) Stock Price Up 10.9%Here's What Happened - MarketBeat
Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD - BioWorld Online
Korro Bio (NASDAQ:KRRO) Shares Gap DownHere's Why - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN
Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks
RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):